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to understanding the mechanisms of this interaction is a thorough 
knowledge of the neuronal and immune cell types involved as well 
as a profound insight into the expression of different players of the 
CRF signaling system in these cells. This review will focus on the 
current data regarding the expression of these CRF-related peptides, 
e.g., CRF, urocortins (UCNs), and CRF receptors, in the GI tract and 
discuss the influence of inflammation on their expression profile, 
with special attention to the different inflammation models used.
CRF, uRoCoRtins, and theiR ReCeptoRs
Although a CRH had already been discovered in 1955 (Saffran 
and Schally, 1955), it was not until 1981 that Vale et al. (1981) 
succeeded in isolating CRF, consisting of 41 amino acids, from the 
ovine hypothalamus. Later studies revealed the presence of highly 
homologous proteins in both mammalian and non-mammalian 
species (Rivier et al., 1983; Thompson et al., 1987; Seasholtz et al., 
1991; Lovejoy and Balment, 1999; Okada et al., 2005). Phylogenic 
analyses  have  shown  that  the  CRF-like  peptides  constitute  an 
ancient lineage, with origin in the Precambrian period as a pep-
tide involved in osmoregulation (Lovejoy and Jahan, 2006; Lovejoy, 
2009). CRF, just like many hormones, is derived from a precursor 
protein, designated as prepro-CRF and consisting of 196 amino 
acids (Furutani et al., 1983; Shibahara et al., 1983). The amount 
of free CRF can be controlled by a CRF-binding protein (Behan 
et al., 1995).
Corticotrophin-releasing factor acts through activation of two 
receptors: CRF1 and CRF2. A third CRF receptor seems to be 
restricted to the catfish species (Arai et al., 2001). CRF receptors 
are G-protein-coupled receptors (GPCRs) of the secretin   receptor 
intRoduCtion
Corticotrophin-releasing factor (CRF), also called corticotrophin-
releasing hormone (CRH; Hauger et al., 2003; Gallagher et al., 2008), 
was first described in the ovine hypothalamus (Vale et al., 1981) and 
is mainly known for its role in the hypothalamus–pituitary–adrenal 
(HPA) axis. Stressors of intrinsic or extrinsic origin induce the 
secretion of CRF from the hypothalamus, which in turn evokes the 
release of adrenocorticotropic hormone (ACTH) from the pituitary 
gland. ACTH finally stimulates glucocorticoid secretion by the adre-
nal cortex (Mawdsley and Rampton, 2005; Kyrou and Tsigos, 2009). 
Stress is known to aggravate gastrointestinal (GI) disorders, such as 
Crohn’s disease (CD), ulcerative colitis (UC), and irritable bowel 
syndrome (IBS; Mawdsley and Rampton, 2005; Hisamatsu et al., 
2007). CD and UC have a clear inflammatory component and hence 
are classified as inflammatory bowel diseases (IBD). The cause of 
symptoms of IBS patients, however, is not clear. Several epidemio-
logical studies have dealt with the influence of (psychological) stress 
on GI disorders, but interpretation is difficult due to considerable 
variation in study design and quality (Mawdsley and Rampton, 
2005; Hisamatsu et al., 2007; Musial et al., 2008; Camara et al., 
2009; Zijdenbos et al., 2009). However, several in vitro and in vivo 
studies indicate a clear influence of CRF and related peptides on GI 
functions and inflammation. This subject has also been touched on 
in other interesting reviews, which discussed the role of CRF in the 
different aspects of intestinal function (Larauche et al., 2009) or the 
influence on different components of the immune response (Kiank 
et al., 2010). It is becoming increasingly clear that neuro-immune 
interaction can substantially influence the immune response in the 
GI tract (Gross and Pothoulakis, 2007). An important prerequisite 
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doi: 10.3389/fnins.2011.00054family, also called class B. They belong to subfamily B2, as do other 
hormone and neuropeptide receptors (Hauger et al., 2003). CRF 
receptors have been reported to couple to several G-proteins, the 
contribution of which depends on cellular and genetic background 
(Blank et al., 2003; Dautzenberg et al., 2004a; Gutknecht et al., 
2009). The main signaling pathway is cAMP-dependent, thus ini-
tiated by Gs proteins and subsequent adenylyl cyclase activation. 
Effects of Gq protein activation, linked to the phospholipase C path-
way, and to a lesser extent Gi/o activation, however, have also been 
observed in relation to CRF receptor stimulation (Hillhouse and 
Grammatopoulos, 2006; Gutknecht et al., 2009). Interpretation of 
the results is further complicated by the cross-talk between differ-
ent G-protein-coupled signaling cascades, converging on the MAP/
ERK pathway, and by interaction between CRF receptors and other 
GPCRs (Brar et al., 2004; Hillhouse and Grammatopoulos, 2006; 
Gutknecht et al., 2009, 2010; Van Kolen et al., 2010). Several splice 
variants of CRF receptors have been identified. In the case of CRF1, 
only the main CRF1(a) isoform was thought to be a functional 
CRF receptor. However, a recent paper by Wu et al. (2011) identi-
fied a functional isoform, CRF1(i), in the BON-N1 cell line, and 
confirmed its expression in human tissue, including the ileum. The 
other variants display low ligand affinity or are unable to induce 
intracellular signaling (Dautzenberg et al., 2001; Pisarchik and 
Slominski, 2004; Karteris et al., 2010). These isoforms might have 
a regulatory influence on CRF1 signaling but although interesting, 
this role remains rather speculative and requires further research 
(Pisarchik and Slominski, 2004; Zmijewski and Slominski, 2010). 
CRF2, on the other hand, exists in three functional splice variants 
(Lovenberg et al., 1995b; Kostich et al., 1998; Hauger et al., 2003). 
Both CRF2(a) and CRF2(b) have been found in mammalian tissues, 
while only CRF2(a) has been described in non-mammalian species 
and CRF2(c) has been detected solely in human tissue (Hauger 
et al., 2003). Studies on mouse and tree shrew CRF2 show higher lig-
and selectivity of CRF2(b) compared to CRF2(a), while the ligand 
selectivity of human CRF2(a) and CRF2(b) splice variants is similar. 
Functionally, these isoforms do not display large differences (Ardati 
et al., 1999; Palchaudhuri et al., 1999; Dautzenberg et al., 2004b). 
In rodents, CRF2(a) is mainly expressed in the central nervous 
system, while CRF2(b) is the main peripheral isoform (Lovenberg 
et al., 1995a; Palchaudhuri et al., 1999; Dautzenberg et al., 2004b); 
in humans, however, CRF2(a) is also the prevalent isoform in the 
periphery (Valdenaire et al., 1997; Kostich et al., 1998). In addition 
to these functional receptor isoforms, several non-functional CRF2 
splice variants have been described. Of interest are soluble forms 
lacking the transmembrane domains, which have been described in 
rodents. These soluble splice variants are not functional receptors 
but could act as ligand scavengers (like the CRF-binding protein), 
influencing CRF signaling (Chen et al., 2005; Wu et al., 2007).
Corticotrophin-releasing factor receptors are also activated by 
other ligands, apart from CRF proper. Important endogenous ago-
nists are the urocortins (UCNs). To date, three urocortin peptides 
have been described in mammals. UCN1 is a 40 amino acid pep-
tide (Vaughan et al., 1995), related to the fish urotensin 1 and the 
amphibian sauvagine (Ichikawa et al., 1982; Lederis et al., 1982; 
Okawara et al., 1988; Stenzel-Poore et al., 1992). UCN2 and UCN3 
were previously also designated as stresscopin-related peptide and 
stresscopin, respectively, and are likely to consist of 38 amino acids 
although lengths of 43 amino acids (for UCN2) and 40 amino 
acids (for UCN3) have also been proposed (Hsu and Hsueh, 2001; 
Lewis et al., 2001; Reyes et al., 2001). Since mammalian UCNs had 
not been described before 1995, the possibility of aspecificity of 
CRF antibodies, i.e., these antibodies possibly also stained UCNs 
in earlier morphological studies, should be considered. UCNs are 
equally or even more important ligands of CRF receptors in spite 
of the receptor’s designation: the receptors show higher affinity for 
UCNs than for CRF. However, marked differences in affinity were 
found between CRF1 and CRF2: UCN1 binds both CRF1 and CRF2, 
whereas UCN2 and UCN3 only bind to CRF2. Comparison of the 
UCNs revealed that the affinity of UCN1 and UCN2 for CRF2 is 
similar but higher than that of UCN3. Furthermore, UCNs show 
a slightly higher affinity for CRF2(b) than for CRF2(a) (Hsu and 
Hsueh, 2001; Lewis et al., 2001; Reyes et al., 2001).
expRession oF CRF-Related peptides in the stomaCh
Given the apparent link between stress and GI disorders, several 
studies have focused on the expression of CRF-related peptides 
(CRF, UCNs, and CRF receptors) in the GI tract. An extensive 
immunohistochemical study of the guinea pig enteric nervous sys-
tem showed CRF immunoreactivity – be it at very low levels – in 
the myenteric plexus; for example, only ∼0.6% of total cell bodies 
in the stomach (the lowest of the GI tract) was CRF positive (see 
below; Liu et al., 2006). CRF was present in both nerve fibers and 
neuronal cell bodies. The fibers were CGRP and tyrosine hydroxy-
lase (TH) negative and CRF was still demonstrable after 7 days of 
organotypic culture, indicating that these CRF-expressing fibers 
are of intrinsic origin. The majority of CRF-positive myenteric 
neurons in guinea pig displayed Dogiel type I morphology (Liu 
et al., 2006). In the rat gastric antrum, Porcher et al. (2006) also 
reported CRF-positive myenteric neuronal cell bodies and fibers, 
along with CRF expression in smooth muscle cells. The immuno-
histochemical results of this study, however, were in disagreement 
with the quantitative PCR data which failed to reveal CRF expres-
sion (Porcher et al., 2006). Accordingly, reverse transcriptase-PCR 
(RT-PCR) data also showed a lack of CRF mRNA in human gastric 
mucosa (Chatzaki et al., 2003).
Data on expression of UCNs in the stomach are rather scarce, 
with most data available for UCN1. This peptide has been found 
to be expressed in the gastric mucosa, in particular in parietal cells, 
in both human and rat (Kozicz and Arimura, 2002; Chatzaki et al., 
2003). Chatzaki et al. (2004b) reported that parietal-like cells in 
gastric glands of the rat co-expressed CRF2 but not CRF1. UCN1 
(co-localized with TH) was also found in fibers of the rat gastric 
enteric plexus (Kozicz and Arimura, 2002; Porcher et al., 2006). In 
contrast to Kozicz and Arimura (2002), Porcher et al. (2006) also 
observed UCN1 in neuronal bodies of the gastric myenteric plexus. 
Finally, UCN1 was detected in serotonin (5-HT)-immunoreactive 
(ir) enterochromaffin cells in rat stomach. However, the latter find-
ing is in contrast to RT-PCR data on gastric UCN1 expression in 
the same study as well as in an earlier report (Harada et al., 1999; 
Porcher et al., 2006), which the authors stated to be due to the 
very low level of RNA expression at the time of sampling. UCN2 
expression in the stomach has been described in mouse, rat as 
well as in human, but only at the mRNA level (Hsu and Hsueh, 
2001; Chen et al., 2004; Porcher et al., 2006). Comparison with 
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CRF-ir neurons co-expressed vasoactive intestinal peptide (VIP), 
which together with their Dogiel type I morphology indicates 
that they are non-cholinergic secretomotor/vasodilator neurons 
(Furness, 2006; Liu et al., 2006). Other studies have focused on the 
rat. The first study in the rat small intestine, performed as early 
as 1984, described CRF-ir neurons and fibers in the duodenal 
myenteric plexus, but not in the submucous plexus (Wolter, 1984). 
The absence of CRF in the submucous plexus reported by Wolter 
(1984) is in contrast with later findings of la Fleur et al. (2005) 
who detected CRF in the nerve fibers of the submucous plexus. 
However, the former study did describe blood vessel-associated 
submucous nerve fibers in the duodenum. CRF in submucous 
nerve fibers has also been observed in the rat jejunum and ileum 
(la Fleur et al., 2005; Sand et al., 2010). In addition, the rat ileum 
has also been reported to contain CRF mRNA, which corroborates 
the immunohistochemical results, according to which CRF was 
located in nerve fibers of the enteric plexuses and – at low levels 
– also in the lamina propria and Paneth cells (la Fleur et al., 2005; 
Sand et al., 2010). The recent study by Sand et al. (2010) speci-
fied that these CRF-ir nerve fibers predominantly co-expressed 
VIP and were located in the lamina propria, circular muscle layer, 
and around enteric neurons. Few CRF-positive fibers were also 
seen around blood vessels and in the longitudinal muscle layer. 
In addition to CRF expression in nerve fibers, the same study 
also described CRF in neuronal somata of the submucous and, 
to a lesser extent, myenteric plexus, strongly co-localizing with 
VIP. Finally, some CRF-ir endocrine cells were observed in the 
crypts of the rat ileum (Sand et al., 2010). The only report in 
mouse describes CRF expression in the lamina propria and in a 
few epithelial cells of the ileum, at both the mRNA and the protein 
level (Wlk et al., 2002).Care should be exercised when interpret-
ing the immunoreactivity that is often described in immune cells. 
For instance, Sand et al. (2010) reported that in their hands, CRF 
immunoreactivity in lamina propria immune cells persisted after 
preabsorption of the antibody, while in other cells it was abolished. 
This illustrates that proper controls should always be included, 
especially when dealing with immunoreactivity in immune cells.
Protein expression of UCNs in the small intestine has mainly 
been described in rat tissue, although there is one paper report-
ing UCN3 expression in the murine muscularis mucosae (Hsu 
and Hsueh, 2001). UCN1 was not found in rat enteric neuronal 
cell bodies but was co-localized with TH in fibers of the enteric 
nervous system, fibers around the Lieberkühn crypts and in some 
enteroendocrine cells in these crypts (Kozicz and Arimura, 2002). 
Since axonal transport had not been blocked for these stainings, 
expression in intrinsic neurons cannot be completely ruled out, 
given observations of a small population of TH-ir intrinsic enteric 
neurons (Chevalier et al., 2008; Qu et al., 2008). The transcript for 
UCN1 was found in both enteric plexuses (Harada et al., 1999). 
UCN2 mRNA has been described in both rat and mouse small 
intestine (Chen et al., 2004; Chang et al., 2007), but the murine 
expression has been reported to be very low for all regions of the 
small intestine (Chen et al., 2004). Throughout the rat small intes-
tine, UCN2 was detected in the epithelium, lamina propria immune 
cells and the enteric plexuses with the highest expression observed 
in the jejunum (Chang et al., 2007). In human small intestine, 
other peripheral tissues in mouse revealed that gastric expression 
of UCN2 was low (Chen et al., 2004). In rat, Porcher et al. (2006) 
demonstrated comparable UCN2 levels in antrum muscle layers 
and mucosa. UCN3 in the stomach, finally, has been demonstrated 
in human tissue and, again, only at the mRNA level (Hsu and 
Hsueh, 2001).
Gastric expression of CRF receptors has been described in human, 
guinea pig, and rat. In guinea pig, CRF1-expressing neurons consti-
tuted about half of the myenteric neurons in the gastric corpus, and 
one-third in the antrum (Liu et al., 2005). In rat, CRF1 expression 
was also reported in the myenteric plexus of the antrum. However, 
in contrast to the data in guinea pig where no co-  localization with 
synapsin was found, CRF1 in rat was co-localized with synapto-
physin, suggestive of presynaptic expression (Porcher et al., 2006). 
One study reported CRF1 expression in enteroendocrine-like cells 
of the mucosal glands in the rat gastric corpus (Chatzaki et al., 
2004b). These cells did not express H
+/K+-ATPase or somatosta-
tin but were found in close proximity to UCN1-expressing cells. 
Moreover, UCN1-expressing nerve fibers have also been described 
in close proximity to the gastric glands hinting at a role of UCN1 
in regulating gastric secretion through the CRF1 receptor (Kozicz 
and Arimura, 2002). Gastric expression of CRF1 was confirmed at 
the mRNA level in both rat and guinea pig (Liu et al., 2005; Porcher 
et al., 2006). In human stomach, however, CRF1 mRNA could not 
be detected, whereas CRF2 mRNA was detectable (Chatzaki et al., 
2006). CRF2 protein expression in human was found in the mucosa, 
where it is possibly involved in the regulation of apoptosis, and in a 
few immune cells in the lamina propria (Chatzaki et al., 2006). In rat, 
protein expression was found in cells expressing H+/K+-ATPase and 
UCN1 in the mucosal glands, indicating expression in parietal cells 
(Chatzaki et al., 2004b). The same study also described expression of 
CRF2 in submucous blood vessels. CRF2, just like CRF1, was found 
to be co-localized with synaptophysin in the myenteric plexus of 
the antrum (Porcher et al., 2006). Quantitative PCR disclosed CRF2 
mRNA in the mucosa and muscle layers of the rat gastric antrum, 
with the highest expression observed in the muscle layers (Porcher 
et al., 2006). A schematic overview of the expression of CRF-related 
peptides is given in Figure 1.
expRession oF CRF-Related peptides in the small 
intestine
In the guinea pig small intestine, half of the myenteric ganglia of 
the jejunum and ileum and about one-third of the duodenal mye-
nteric ganglia contained at least one CRF-positive neuron. CRF-ir 
neurons, just like those in the stomach, mainly display Dogiel type I 
morphology (Liu et al., 2006). CRF immunoreactivity appeared 
to be higher in the guinea pig submucous plexus with all ganglia 
containing CRF-ir neurons, which accounted for about one-third 
of the total amount of submucous neurons. Dogiel type I was 
again the predominant morphological phenotype (Liu et al., 2006). 
The same study also investigated the chemical coding of the ileal 
neuronal bodies after colchicine treatment and found that CRF in 
myenteric neurons was co-expressed with choline acetyltransferase 
(ChAT), nitric oxide synthetase (NOS), and, to a lesser extent, sub-
stance P (SP; Liu et al., 2006). The neurochemical coding strongly 
suggests that CRF is expressed in descending interneurons and/
or motor neurons, but not in intrinsic primary afferent neurons 
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markers. Co-localization between CRF1 and NOS, VIP, or calretinin 
(CalR) was absent in the guinea pig ileum (Liu et al., 2005; Bisschops 
et al., 2006). The expression of CRF1 in the guinea pig is thus 
complementary to that of CRF and indeed Liu et al. (2005) showed 
that neurons with IPAN characteristics are excited by CRF. CRF 
signaling could thus be a basis of direct communication between 
enteric motorneurons and IPANs. In mouse, only one study has 
reported on the expression of CRF1 mRNA in cells of the lamina 
propria and epithelium (Wlk et al., 2002). In rat, Porcher et al. 
(2005) observed CRF1 in enteric neurons with Dogiel type II mor-
phology and innerve fibers, although these findings are in contrast 
with the results of another study describing the absence of CRF1 
in the duodenal submucosa (Chatzaki et al., 2004b). Quantitative 
UCN2 mRNA was absent, while UCN3 mRNA was detected in all 
regions of the small intestine, except for the ileocecal area (Hsu 
and Hsueh, 2001).
In guinea pig, CRF1 was found to be expressed in about one-
third of the myenteric neurons and half of the submucous neu-
rons, with little variation between the different regions of the small 
intestine (Liu et al., 2005). CRF1 was not found in interstitial cells 
of Cajal, enteroendocrine cells, or muscle fibers of this species (Liu 
et al., 2005). Almost all enteric CRF1-ir neurons in the guinea pig 
ileum  were  cholinergic,  and  strong  co-labeling  with  calbindin 
(CalB) was observed in the myenteric plexus (Liu et al., 2005),indi-
cating that CRF1 is mainly expressed in IPANs, at least in the ileal 
myenteric plexus (Furness, 2006). In the submucous plexus of the 
ileum, all CalB-ir, and all SP-ir neurons also displayed CRF1, while 
Figure 1 | Schematic overview of the expression of CrF-related proteins 
in the stomach. Regular font indicates that protein expression has been 
described, italic font indicates that mRNA expression has been described, bold 
font indicates that expression has been described at mRNA and protein level. 
MP , myenteric plexus; SP , submucous plexus; r, rat; m, mouse; gp, guinea pig; h, 
human; o, ovine fetus.
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2007). Mucosal expression of UCN1 has only been reported in very 
few cells of the rat colon (Kozicz and Arimura, 2002). In humans, 
strong UCN1 expression was observed in mononuclear cells of 
the lamina propria (Muramatsu et al., 2000; Bhatia and Tandon, 
2005; Saruta et al., 2005), appearing after birth and increasing up 
to adulthood (Muramatsu et al., 2000). However, Muramatsu et al. 
(2000) reported that the enteric plexuses were devoid of UCN1, 
whereas with Saruta et al. (2005) described a weak expression in the 
enteric plexuses, epithelial (enterochromaffin) cells and vascular 
endothelium, and smooth muscle. UCN2 mRNA was absent in the 
human colon, very low in the murine colon, but abundant along 
the entire duodenal–rectal region in the rat colon (Hsu and Hsueh, 
2001; Chen et al., 2004; Chang et al., 2007). Protein expression in 
the colon, however, was lower than in the jejunum and located 
in epithelial cells, lamina propria immune cells, and enteric neu-
rons (Chang et al., 2007). The presence in epithelium and enteric 
neurons also holds true for the rectum, but expression levels were 
the lowest of the duodenal–rectal region (Chang et al., 2007). The 
same study also mentioned UCN2 immunoreactivity – be it faint 
and inconsistent – in Peyer’s patches. UCN3 expression has been 
described in human colon, in particular in the enteric plexuses, 
smooth muscle, endothelium and – at a low level – also in lamina 
propria mononuclear cells (Hsu and Hsueh, 2001; Saruta et al., 
2005).  Immunohistochemical  results  further  revealed  that  the 
UCN3 signal was localized in both enteric neurons and S-100-ir 
enteric glial cells. The signal was strongest in the myenteric plexus. 
Immunohistochemistry, unlike in situ hybridization, showed the 
expression of UCN3 in serotonergic enterochromaffin cells and 
epithelium, be it at rather low levels (Saruta et al., 2005). These 
contrasting results thus could arise from differences in sensitiv-
ity between the employed techniques. To our knowledge, data on 
UCN3 expression in rodents are currently lacking.
Expression of CRF1 mRNA and protein has been detected in the 
myenteric plexus in both the guinea pig and rat colon (Chatzaki 
et al., 2004a; Liu et al., 2005, 2010; Kimura et al., 2007; Yuan et al., 
2007; O’malley et al., 2010b). In guinea pig, the signal for CRF1 
was also found in the submucous plexus (Liu et al., 2005), while 
the data in rat are inconsistent (Chatzaki et al., 2004a; Yuan et al., 
2007; O’malley et al., 2010b). Expression of CRF1 in the guinea pig 
colon is similar to that in the ileum, albeit with some subtle dif-
ferences. Almost all CRF1-ir myenteric neurons were cholinergic, 
and some expressed CalB, as such resembling their counterparts 
in the ileum. However, about one-third of the colonic myenteric 
neurons was nitrergic, whereas none of the ileal CRF1-ir neurons 
of the myenteric plexus was nitrergic. The proportion of CRF1-ir 
neurons (40%) was comparable to that in the ileum (Liu et al., 2005, 
2010). Again, CRF1-ir fibers were synapsin-negative in guinea pig, 
indicating that the expression of CRF1 is not located presynaptically 
(Liu et al., 2005).The expression of CRF1 seems to be markedly 
higher in rat compared to guinea pig, with almost all myenteric 
neurons displaying CRF1 immunoreactivity (Chatzaki et al., 2004a; 
Yuan et al., 2007). Activation by CRF induced the neuronal activa-
tion marker c-Fos in cholinergic and nitrergic neurons with Dogiel 
type I morphology (Yuan et al., 2007). Interestingly, Kimura et al. 
(2007) showed that CRF1-ir myenteric fibers were located around 
UCN1-ir cell bodies. Given the high expression of UCN1, and 
PCR revealed that CRF1 expression was higher in the muscle layers 
and mucosa of the rat duodenum compared to the ileum (Porcher 
et al., 2005). As such, a species difference in CRF1 expression in 
muscle layers can be observed between rat and guinea pig (Liu 
et al., 2005). Furthermore, the regional differences in the expression 
level of CRF1 are opposite to those of CRF2, in which case mRNA 
expression was higher in the ileum, while duodenal muscle layers 
were devoid of CRF2 message (Porcher et al., 2005). Another study 
stated that there was no expression of CRF2 mRNA whatsoever in 
the rat duodenum, in contrast to the jejunum and ileum (Chang 
et al., 2007). In murine tissue, CRF2 mRNA has been found in the 
submucosa and at the base of the villi in the duodenum (Perrin 
et al., 1995) and – at low levels – also in the lamina propria and 
epithelium of the ileum (Wlk et al., 2002). Morphological data 
provide evidence for the presence of CRF2 in enteric neurons and 
nerve fibers in rat, co-expressing synaptophysin. These fibers dis-
played varicosities that encircled CRF2-negative neurons. Some 
CRF2 was found in the duodenal glands (Chatzaki et al., 2004b) 
and in 5-HT-negative epithelial cells in the villi (Porcher et al., 
2005). CFR2 expression was not found the small intestine in guinea 
pig (Liu et al., 2005), while only a few lamina propria cells were 
stained in murine ileum (Wlk et al., 2002), which again points to 
significant species differences in CRF receptor expression. Figure 2 
summarizes the available data on expression of CRF-related pep-
tides in the small intestine.
expRession oF CRF-Related peptides in the Colon
Prepro-CRF has been described in epithelial cells, the lamina pro-
pria, and the submucosa of the rat colon (Barreau et al., 2007). The 
colon hosts the largest number of CRF-ir myenteric neurons of the 
guinea pig GI tract – albeit still a mere 2.8% of all myenteric neu-
rons – with a predominantly Dogiel type I morphology. Likewise, 
the proportion of CRF-ir submucous neurons was also highest in 
the guinea pig colon, but in this case amounted to close to 40% of 
the total submucous neurons. These neurons all had Dogiel type I 
morphology (Liu et al., 2006). In the rat colon, CRF-ir was present 
in a moderate number of myenteric neurons, accounting for about 
5–10% of the total myenteric neurons (Kimura et al., 2007; Sand 
et al., 2010). Almost 60% of the CRF-ir neurons in rat were VIPergic 
in both enteric plexuses. CRF-ir nerve fibers in the rat colon were 
also mostly VIPergic and were mainly located in the mucosa and 
submucous ganglia and in the circular muscle layer (Sand et al., 
2010). Non-neuronal expression of CRF (co-expressed with 5-HT) 
was found in enteroendocrine cells in rat and human (Kawahito 
et al., 1994; Sand et al., 2010), and in other epithelial cells and 
monocytes in human (Kawahito et al., 1995). The results, however, 
are in contrast with other reports in which the rat colon was found 
to lack any CRF mRNA or proteins (Harada et al., 1999; la Fleur 
et al., 2005). For the rat cecum, only a very weak expression of CRF 
has been mentioned in the enteric plexuses (van Tol et al., 1996).
Expression of UCN1 in the rat colon is markedly higher than 
that of CRF and seems to be located – at least partly – in a differ-
ent neuronal population (Harada et al., 1999; Kimura et al., 2007). 
UCN1-ir neurons constitute approximately 70 and 80% of submu-
cous and myenteric neurons, respectively. While a large proportion 
of the CRF-ir neurons were VIPergic (Sand et al., 2010), UCN1 was 
present in most cholinergic myenteric neurons. Approximately 65% 
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et al., 2004a; O’malley et al., 2010a,b). One paper describes the 
expression of CRF1 in the distal colon of the ovine fetus, where 
it was expressed in muscle tissue, enteric ganglia, and goblet cells. 
Generally CRF1 immunoreactivity is seen to increase during ges-
tation, especially in the enteric ganglia (Lakshmanan et al., 2008). 
Muramatsu et al. (2000) showed CRF1 mRNA expression in human 
lamina propria mononuclear cells. A more recent study by Wallon 
et al. (2008) on human colon biopsies also disclosed CRF1 expres-
the highly probable co-localization of UCN1, ChAT, and 5-HT, it 
could be hypothesized that these (UCN1-ir) neurons, at least in 
rat, are mainly descending interneurons involved in secretomotor 
and motility reflexes that secrete UCN1 and that these neurons as 
such might influence the excitability of CRF1-expressing enteric 
fibers (Furness, 2006; Kimura et al., 2007; Yuan et al., 2007; Qu 
et al., 2008). Indeed, a functional study in guinea pig confirmed that 
UCN1 is capable of exciting CRF1-expressing myenteric neurons 
in the colon (Liu et al., 2010). Non-neuronal expression of CRF1 
Figure 2 | Schematic overview of the expression of CrF-related proteins 
in the small intestine. Regular font indicates that protein expression has been 
described, italic font indicates that mRNA expression has been described, bold 
font indicates that expression has been described at mRNA and protein level. 
MP , myenteric plexus; SP , submucous plexus; r, rat; m, mouse; gp, guinea pig; h, 
human; o, ovine fetus.
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1996). A recent study, using an E. Coli lipopolysaccharide (LPS)-
induced colitis model, equally reported increased CRF levels in the 
enteric plexuses. At the mRNA level, CRF expression was found to 
be increased throughout the colonic mucosa and submucosa. The 
largest changes were observed in the proximal colon and mainly 
in samples combining submucosa and muscle layers (Yuan et al., 
2010). In a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced coli-
tis model in rats, CRF2 expression, present on myenteric neurons 
and macrophages, decreased in the early phase (days 1–3) of inflam-
mation, which is different from the situation in the murine ileum 
(Wlk et al., 2002; Chang et al., 2007), possibly as a consequence of 
species, regional or model dissimilarities. The CRF2 down regulation 
observed after TNBS-induced colitis in rat seems to contrast with the 
upregulation of the agonist UCN2, the mRNA expression of which 
increased in the early and late stages (days 12–15) of inflammation 
due to infiltration of UCN2-expressing immune cells and fibrosis 
by UCN2-expressing fibroblasts. Another study revealed decreased 
UCN2 immunoreactivity in the myenteric plexus following TNBS-
induced colitis (Chang et al., 2007). This decrease in CRF2 expres-
sion might be a response compensating for the increased presence 
of UCN2, although this regulation remains speculative. A study by 
Moss et al. (2007) performed on a graft of human fetal intestine in 
immunodeficient (SCID) mice in which inflammation had been 
induced by C. difficile toxin A, demonstrated increased mucosal 
UCN2 mRNA expression (after 6 h) and upregulated mucosal 
CRF2 expression, which is in line with the observations made in 
the murine toxin A model (Wlk et al., 2002; Moss et al., 2007). 
Although it is an interesting method to study the intrinsic inflam-
matory process in the human intestine, this model naturally lacks 
a number of extrinsic factors influencing inflammation.
All other data on the expression of CRF-related peptides during 
inflammation were gathered from human biopsies. In Helicobacter 
pylori-induced gastritis, no induction of gastric CRF expression 
could be found (Chatzaki et al., 2003). However, a marked increase 
in UCN1 expression was found in epithelial and inflammatory 
cells. The highest increase in UCN1 expression was observed dur-
ing regression and correlated well with the successful eradication 
of the H. pylori infection, leading the authors to hypothesize a 
protective role for UCN1 (Chatzaki et al., 2003). This finding again 
indicates that CRF itself may not be the main agonist for the CRF 
receptors, at least not in the stomach. Increased CRF expression was 
observed in monocytes, but not in epithelial cells, in UC biopsies 
compared to healthy samples (Kawahito et al., 1995). Again, other 
CRF receptor agonists were also reported. UCN1 was present in 
lamina propria plasma cells, but not in macrophages, in UC biopsies 
where it was partially co-expressed with CRF1 and CRF2 (Saruta 
et al., 2004). The UCN1 levels were found to be lower in biopsies 
from glucocorticoid-treated patients and higher in case of more 
severe inflammation (Saruta et al., 2004). The same study also dis-
closed UCN1 in mucosal cells, some of which were identified as 
enterochromaffin cells (Saruta et al., 2004). Another study on UC 
and also CD biopsies, reported increased epithelial expression of 
both UCN2 and CRF2 in regions with active colitis compared to 
non-inflamed regions of the same patients (Moss et al., 2007). The 
changes in the expression of CRF-related peptides are   summarized 
in Table 1.
sion in subepithelial cells, which were identified as mast cells by 
co-localization with tryptase. However, these authors did not find 
any CRF1 on other cell types, which is in disagreement with the 
animal studies, although it should be mentioned that the myenteric 
plexus was not included in the studied biopsies. CRF2 has also been 
found in human lamina propria mononuclear cells, and faint CRF2 
expression has been observed in epithelial cells, both at them RNA 
and the protein level (Muramatsu et al., 2000; Saruta et al., 2005).
Furthermore, CRF2, unlike CRF1, has also been localized in the 
enteric plexuses, the endothelium, and vascular smooth muscle, 
which closely resembles the expression pattern of UCN1 and UCN3 
in the human colon described in the same study (Saruta et al., 
2005). In rat, the message for CRF2 has been reported in both the 
colon and the rectum (Chatzaki et al., 2004a; Chang et al., 2007). 
This expression was confirmed at the morphological level with 
CRF2 being located in lamina propria cells and myenteric plexus 
fibers again observed in close proximity to UCN1-ir cell bodies, 
as was also the case for CRF1 (Kimura et al., 2007; O’malley et al., 
2010a,b). However, these findings are in contrast with the results 
of the first report on CRF receptor expression in the rat colon 
where goblet cells and submucosal blood vessels, but not enteric 
neurons or fibers, were found to be CRF2-ir (Chatzaki et al., 2004a). 
The neurochemical coding of the CRF2-expressing neurons in rat 
has not been investigated. In guinea pig, myenteric synapsin- and 
CRF2-expressing nerve fibers have been described, but expression 
in cell bodies was very low. These infrequent CRF2-ir myenteric 
cell bodies all displayed CalB and ChAT immunoreactivity but were 
negative for NOS (Liu et al., 2010), suggesting that these were IPANs 
(Furness, 2006). Another study did not report any CRF2 expression 
in the enteric plexuses of guinea pig (Bisschops et al., 2006).Finally, 
expression of CRF2, just like that of CRF1, was investigated in the 
ovine fetus: CRF2 expression in muscle layers was found to decrease 
with gestation, while neuronal expression was limited to fibers of 
unspecified origin (Lakshmanan et al., 2008). An overview of the 
colonic expression of CRF-related peptides is provided in Figure 3.
inFluenCe oF inFlammation on the expRession oF 
CRF-Related peptides
Given the apparent links between stress and GI disorders (Bhatia 
and Tandon, 2005), it is definitely worthwhile to investigate the GI 
expression of CRF-related peptides during inflammation. Although 
this topic has been dealt with in a number of studies, morphologi-
cal data are generally still limited. The results gathered so far tend 
to suggest that the expression of CRF-related peptides is increased 
in both inflammatory animal models and IBD biopsies. In the 
murine ileum, CRF and CRF receptor expression were found to 
be increased within 1 h after Clostridium difficile toxin A-induced 
inflammation. CRF expression was mainly located on subepithelial 
cells, while both CRF receptors were found in both lamina propria 
cells and epithelial cells. This increased expression at least partially 
acted in a pro-inflammatory manner since blockade of CRF1 led to 
decreased inflammation (Wlk et al., 2002). Other animal studies all 
focused on the rat species. Increased CRF expression was observed in 
inflammatory cells, mesenchymal cells, and in the myenteric plexus, 
both at mRNA and protein level following a cecal inflammation 
induced with peptidoglycan-polysaccharides (van Tol et al., 1996). 
Treatment of isolated lamina propria mononuclear cells from the 
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activation stimulates duodenal contractions and colonic motor activ-
ity (Mancinelli et al., 1998; Maillot et al., 2000; Porcher et al., 2005; 
Kimura et al., 2007; Yuan et al., 2007). In rat, CRF1 promotes while 
CRF2 inhibits colonic hypersensitivity (Million et al., 2003, 2006; 
Greenwood-Van Meerveld et al., 2005). The effects of CRF receptor 
signaling on immune components seem to involve several cell types, 
and often have an impact on the cytokine profile. Although some data 
originate from regions other than the GI tract, it is nonetheless clear 
that the role of CRF-related peptides in GI inflammation needs further 
Role oF CRF-Related peptides in Gi inFlammation
Apart from one report on TNBS-induced colitis in rats (Chang et al., 
2007), there seems to be agreement in the literature that the compo-
nents of the CRF signaling pathway increase with inflammation. In 
addition, there are plenty of indications that changes in the expression 
pattern of CRF-related peptides may have an important impact on 
GI functions. Functional studies clearly revealed that activation of 
CRF receptors often results in contrasting effects, depending on the 
GI region. For example, activation of CRF2 inhibits gastric emptying 
and ileal contraction (Pappas et al., 1985; Nozu et al., 1999; Wang 
Figure 3 | Schematic overview of the expression of CrF-related proteins 
in the colon. Regular font indicates that protein expression has been described, 
italic font indicates that mRNA expression has been described, bold font 
indicates that expression has been described at mRNA and protein level. MP , 
myenteric plexus; SP , submucous plexus; r, rat; m, mouse; gp, guinea pig; h, 
human; o, ovine fetus.
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Protein Organ/cell type inflammation expr. level Species effect references
mrNA Prot.
CrF
ileum C. Difficile toxin A X X Mouse ↑ After 60 min, 
pro-inflammatory
Wlk et al. (2002)
                            Cecum
Inflammatory cells, 
mesenchymal cells, 
myenteric plexus
Peptidoglycan-
polysaccharides
X X Rat ↑ van Tol et al. (1996)
Colon Lipopolysaccharides X Rat ↑ Yuan et al. (2010)
ENS Lipopolysaccharides X Rat ↑ Yuan et al. (2010)
Inflammatory cells, 
epithelium
Ulcerative colitis X X Human ↑ In monocytes, not in 
epithelium
Kawahito et al. 
(1994)
uCN1
Stomach
Epithelium, inflammatory 
cells
H. pylori gastritis X X Human ↑ Mainly during 
regression
Chatzaki et al. 
(2003)
                            Colon
Lamina propria immune 
cells and mucosal cells 
near base of crypts
Ulcerative colitis X X Human ↑ With severity of 
inflammation, ↓ in 
glucocorticoid-treated 
patients
Saruta et al. (2004)
uCN2
Colon TNBS Colitis X Rat ↑ In early phase, control 
levels in middle phase, 
↑ in late phase
Chang et al. (2007)
Muscle layers: myenteric 
plexus, fibroblasts
TNBS Colitis X Rat Fibrosis, ↓ in myenteric 
plexus
Chang et al. (2007)
Lamina propria: 
inflammatory cells, 
fibroblasts
TNBS Colitis X Rat ↑, Fibrosis Chang et al. (2007)
Mucosa Fetal human intestine 
xenograft in mice + C. 
difficile toxin A
X Human/
mouse
↑ After 6 h due to 
infiltrating immune cells
Moss et al. (2007)
Colitis ulcerosa, 
Crohn’s disease
X Human ↑ In active colitis Moss et al. (2007)
CrF1
ileum
Lamina propria and 
epithelium
C. difficile toxin A X Mouse ↑ After 30–60 min. Wlk et al. (2002)
                            Colon
Lamina propria immune 
cells
Ulcerative colitis X ↑ Saruta et al. (2004)
CrF2
ileum
Lamina propria and 
epithelium
C. difficile toxin A X X Mouse ↑ After 30–60 min. Wlk et al. (2002)
Colon TNBS colitis X ↓ In early phase, control 
levels in middle phase 
and late phase
Chang et al. (2007)
(Continued)
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Araki et al., 2005; Rakoff-Nahoum et al., 2006) and is associated with 
IBD pathology in humans (De Jager et al., 2007). A recent study 
employing a dextran sulfate sodium (DSS)-induced colitis model in 
mouse showed that CRF-deficient mice have a lower expression of 
Tlr4 before the onset of inflammation and that inflammation is more 
severe in CRF-deficient mice. This effect on inflammation appears 
not to be due to the decreased glucocorticoid levels observed in these 
mice (Chaniotou et al., 2010). Another recently published paper using 
the murine DSS-induced colitis model again disclosed a contrasting 
influence at the receptor level: CFR1 knockout (CRF1−/−) mice showed 
decreased  inflammation,  while  CRF2−/− mice  displayed  increased 
intestinal inflammation, an effect that could be mimicked by antago-
nizing the receptors in wildtype mice. This study, however, did not 
investigate Tlr expression (Im et al., 2010). Although these data suggest 
an in vivo anti-inflammatory effect of CRF2, other results show a 
pro-inflammatory  influence,  possibly  depending  on  the  type  of 
inflammation. CRF2 knockout has been shown to lead to attenuated 
inflammation in C. difficile toxin A-induced ileal inflammation. The 
pro-inflammatory role of CRF2 in this study was largely mediated by 
chemokine induction, since blocking this receptor reduced IL-6, MCP-
1, and keratinocyte chemokine levels and neutrophil infiltration 
(Kokkotou et al., 2006). The pro-inflammatory influence of CRF was 
underscored in another study from the same group, which showed 
that CRF−/− mice developed less severe inflammation. The authors 
linked the CRF deficiency to the absence of a toxin A-induced increase 
in SP levels (Anton et al., 2004). Wlk et al. (2002) demonstrated that 
CRF receptor antagonists reduced the rise in TNFα and IL-1β and 
gave rise to histological changes in C. difficile toxin A-induced ileitis. 
They showed that part of this effect is mediated through the CRF1 
receptor, but did not exclude involvement of CRF2, which has indeed 
been reported by Kokkotou et al. (2006; see above). The pro-inflam-
matory effect of CRF in C. difficile toxin A-induced ileal inflammation 
was also reported in rat (la Fleur et al., 2005). Interestingly, this study 
showed that intestinal CRF knockdown, but not UCN2 knockdown, 
completely ablated inflammation and increased CRF1   expression in 
inflamed tissue, which suggests an important role of CRF1 in the 
investigation. It is known that CRF leads to increased colonic perme-
ability in rats (Santos et al., 1999; Saunders et al., 2002), a potential 
pro-inflammatory event. Further research has revealed that this effect 
is at least in part mediated by activation of mast cells through a CRF 
receptor-dependent mechanism, leading to the release of nerve growth 
factor (NGF; Castagliuolo et al., 1996; Eutamene et al., 2003; Barreau 
et al., 2007; Teitelbaum et al., 2008; Wallon et al., 2008). A study with 
an in vitro model of endothelial cells showed that CRF influences 
endothelial activation depending on the cellular genotype, and it was 
hypothesized that CRF1 acts anti-inflammatory by counteracting the 
effect of pro-inflammatory cytokines, while CRF2 potentiates this 
pro-  inflammatory effect (Cantarella et al., 2001), which again points 
to a contrasting function of these receptors. The pro-inflammatory 
capacity of CRF2 has also been described in human colonocyte cell 
lines where CRF2 activation by UCN2 resulted in induction of NF-κB 
and subsequent increased release of the chemoattractants interleukin 
8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1; Kokkotou 
et al., 2006; Moss et al., 2007). As discussed before, production of 
CRF2 and UCN2 is increased in human colitis, an effect that could 
be mimicked in these colonocyte cell lines by stimulation with inflam-
matory agents, such as TNFα and C. difficile toxin A (Moss et al., 
2007). In vitro treatment of murine macrophages with CRF receptor 
agonists leads to the anti-inflammatory inhibition of TNFα release 
in the early stages of the inflammatory response, but to increased 
TNFα transcription and release in the late stages (Tsatsanis et al., 
2007). An earlier study from the same group also attributed anti-
inflammatory potency to CRF2 through the induction of macrophage 
apoptosis (Tsatsanis et al., 2005). Additionally, the transcription and 
expression of the toll-like receptor (Tlr) four in macrophages could 
be increased by stimulating CRF2 (Tsatsanis et al., 2006). Although 
these data clearly show that Tlr4-induced macrophage activation is 
stimulated by CRF2, caution should be exercised when extrapolating 
these results to the in vivo situation considering the effects of Tlr4 on 
the entire inflammatory process. Indeed, the in vivo data on the Tlr 
attribute an important role in intestinal immune homeostasis to these 
receptors (Cario and Podolsky, 2005). Deficiency in their signaling 
pathways – in particular in the case of Tlr4 – leads to increased intes-
Myenteric plexus TNBS colitis X Rat ↓ Chang et al. (2007)
Lamina propria immune 
cells
Ulcerative colitis X Human ↑ Saruta et al. (2004)
TNBS colitis X Rat Infiltrating 
macrophages, 
decreased after early 
stage
Mucosa Fetal human intestine 
xenograft in mice + C. 
difficile toxin A
X Human/
mouse
↑ After 6 h Moss et al. (2007)
Colitis ulcerosa, 
Crohn’s disease
X X Human ↑ In active colitis Moss et al. (2007)
Table 1 | Continued
Protein Organ/cell type inflammation expr. level Species effect references
mrNA Prot.
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ConCludinG RemaRks
Numerous  studies  clearly  demonstrate  that  CRF,  CRF-related 
  peptides and their receptors are widely distributed throughout the 
GI tract. However, important species differences in the expression 
patterns of these peptides and receptors were found at the cellular 
level. Moreover, characterization of the exact cellular (sub)type 
in which these peptides and their receptors are expressed is often 
lacking, especially in case of enteric neurons and immune cells. 
It is nevertheless clear that signaling of and through CRF-related 
peptides can have an important influence on the course of (GI) 
inflammation. CRF is known as an important stress-related peptide 
in the central nervous system, but may definitely claim a role in 
the periphery as well. The influence of CRF signaling on intestinal 
sensitivity, permeability and GI transit contributes to symptoms 
in IBD, while effects on immune cell activation, cytokine release 
and angiogenesis directly act on the course of inflammation. It 
should be emphasized, however, that UCNs are likely to play an at 
least equally important role. The differences in outcome depend-
ing on the inflammation model, activated receptors and involved 
ligands suggest that the signaling pathways of CRF-related peptides 
form an interacting and finely balanced system. Disturbances in 
this balance likely contribute to GI inflammatory disorders and 
manipulation of this system could open up new treatment options 
for these disorders. Further research remains necessary to gain full 
insight into the pathways involved, but the available data certainly 
warrant future efforts in unraveling the role of CRF-related peptides 
in GI inflammation.
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pro-inflammatory effect of CRF in rat. In murine TNBS-induced 
colitis, CRF knockout also reduced inflammation with a decline in 
local IL-1β upregulation (Gay et al., 2008). Surprisingly, these effects 
of CRF are in contrast to reports on UCN1: UCN1, which binds to 
the same receptors as CRF – even with higher affinity – has been 
ascribed anti-inflammatory properties. Two studies by Gonzalez-Rey 
et al. (2006a,b), who used an endotoxemia model or TNBS-induced 
colitis in the mouse, revealed an influence of UCN1 on the intestinal 
cytokine profile. Treatment of endotoxemic animals with UCN1 suc-
cessfully ablated histological changes and reduced several pro-inflam-
matory cytokines and chemokines, yet also increased the levels of the 
anti-inflammatory IL-10, systemically as well as locally, including in 
the small intestine (Gonzalez-Rey et al., 2006a). Comparable results 
were obtained in TNBS-induced colitis with the induction of a clear 
anti-inflammatory cytokine profile that promoted regulatory T cell 
responses but reduced Th1 responses after treatment with UCN1 
(Gonzalez-Rey et al., 2006b). The contrasting results between CRF 
and UCN1, which both act on the same receptors, may be attributed 
to their different distribution patterns (see above), which would imply 
a tightly regulated interplay between different CRF-related peptides, 
all contributing to a delicate balance that influences the intestinal 
immune response. A final pathway in which inflammation is influ-
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